Immune Therapy Opportunities in Ovarian Cancer.

Details

Serval ID
serval:BIB_71D55C2B15BF
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Immune Therapy Opportunities in Ovarian Cancer.
Journal
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Author(s)
Kandalaft L.E., Odunsi K., Coukos G.
ISSN
1548-8756 (Electronic)
ISSN-L
1548-8748
Publication state
Published
Issued date
05/2020
Peer-reviewed
Oui
Volume
40
Pages
1-13
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Immunotherapy has emerged as a highly promising approach in the treatment of epithelial ovarian cancer (EOC). Immune checkpoint blockade (ICB) therapy, PARP inhibitors (PARPis), neoantigen vaccines, and personalized T-cell therapy have been associated with encouraging clinical activity in a small subset of patients. To increase the proportion of patients who are likely to derive benefit, it will be important not only to generate sufficient numbers of antitumor T cells but also to overcome multiple inhibitory networks in the ovarian tumor microenvironment (TME). Therefore, a major direction is to develop biomarkers that would predict responsiveness to different types of immunotherapies and allow treatment selection based on the results. Moreover, such biomarkers would allow rational combination of immunotherapies while minimizing toxicities. In this review, we provide progress on immune therapies and future directions for maximally exploiting immune-based strategies for the treatment of ovarian cancer.
Pubmed
Create date
14/06/2020 20:16
Last modification date
17/09/2020 5:26
Usage data